79 related articles for article (PubMed ID: 35706933)
1. An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants.
Lu J; Zhang Y; Qi D; Yan C; Wu B; Huang JH; Yao J; Wu E; Zhang G
Heliyon; 2022 Jun; 8(6):e09660. PubMed ID: 35706933
[TBL] [Abstract][Full Text] [Related]
2. Theanine from tea and its semi-synthetic derivative TBrC suppress human cervical cancer growth and migration by inhibiting EGFR/Met-Akt/NF-κB signaling.
Liu J; Sun Y; Zhang H; Ji D; Wu F; Tian H; Liu K; Zhang Y; Wu B; Zhang G
Eur J Pharmacol; 2016 Nov; 791():297-307. PubMed ID: 27612630
[TBL] [Abstract][Full Text] [Related]
3. Suppression of proliferation and migration in highly-metastatic lung cancer cells as well as tumor growth by a new synthesized compound TBrC and its molecular mechanisms of action.
Ji D; Wang Y; Zhang H; Chen L; Liu X; Sun F; Liu K; Yao J; Zhang G
Cytotechnology; 2014 Dec; 66(6):899-911. PubMed ID: 24132498
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives.
Zhang G; Ye X; Ji D; Zhang H; Sun F; Shang C; Zhang Y; Wu E; Wang F; Wu F; Tian H; Liu X; Chen L; Liu K; Wang Y; Liu H; Zhang W; Guan Y; Wang Q; Zhao X; Wan X
Oncotarget; 2014 Sep; 5(18):8528-43. PubMed ID: 25138052
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the Impact of Mutations on the Binding Efficacy of SARS-CoV-2 Omicron and Delta Variants With Human ACE2 Receptor.
Khan A; Khan SA; Zia K; Altowyan MS; Barakat A; Ul-Haq Z
Front Chem; 2022; 10():892093. PubMed ID: 35755247
[TBL] [Abstract][Full Text] [Related]
6. Comparative Structural Analysis of Human ACE2 Receptor with Spike Protein of SARS-CoV-2 Variants: Implications to Understand Infectivity of the Virus.
Koley T; Goswami A; Kumar M; Upadhyay N; Hariprasad G
Adv Appl Bioinform Chem; 2022; 15():21-27. PubMed ID: 35734581
[TBL] [Abstract][Full Text] [Related]
7. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike - ACE2 complexes reveal distinct changes between both variants.
Socher E; Heger L; Paulsen F; Zunke F; Arnold P
Comput Struct Biotechnol J; 2022; 20():1168-1176. PubMed ID: 35251533
[TBL] [Abstract][Full Text] [Related]
9. Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants.
Alonzi T; Aiello A; Repele F; Falasca L; Francalancia M; Garbuglia AR; Delogu G; Nicastri E; Piacentini M; Goletti D
Cell Death Discov; 2022 Jun; 8(1):288. PubMed ID: 35705564
[TBL] [Abstract][Full Text] [Related]
10. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
[TBL] [Abstract][Full Text] [Related]
11. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
[TBL] [Abstract][Full Text] [Related]
12. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
[TBL] [Abstract][Full Text] [Related]
13. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
[TBL] [Abstract][Full Text] [Related]
14. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses.
Shah M; Ung Moon S; Hyun Kim J; Thanh Thao T; Goo Woo H
Comput Struct Biotechnol J; 2022; 20():2042-2056. PubMed ID: 35495107
[TBL] [Abstract][Full Text] [Related]
16. Molecular Dynamics Studies on the Structural Stability Prediction of SARS-CoV-2 Variants Including Multiple Mutants.
Choi KE; Kim JM; Rhee JE; Park AK; Kim EJ; Yoo CK; Kang NS
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563345
[TBL] [Abstract][Full Text] [Related]
17. Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis.
Ortega JT; Jastrzebska B; Rangel HR
Pathogens; 2021 Dec; 11(1):. PubMed ID: 35055993
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis.
Huang HC; Liao CC; Wang SH; Lee IJ; Lee TA; Hsu JM; Kuo CT; Wang J; Hsieh WC; Chang SJ; Chen SY; Tao MH; Lin YL; Lai YJ; Li CW
Am J Cancer Res; 2021; 11(10):4994-5005. PubMed ID: 34765306
[TBL] [Abstract][Full Text] [Related]
19. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
20. Study on the mechanism of active components of Liupao tea on 3CL
Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
